Fuji Yakuhin Co., Ltd.
Quick facts
Phase 3 pipeline
- FFI-1010 · Oncology
FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. - FYU-981
FYU-981 is an investigational therapeutic agent in phase 3 development by Fuji Yakuhin Co., Ltd.
Phase 2 pipeline
- 14C-FYU-981 · Diabetes
14C-FYU-981 is a selective and potent inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: